The Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety data that raises the chances of approval when pivotal trials read ...

Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering drug inclisiran before they got a good look at the data – and it looks ...

Inclisiran can achieve substantial and consistent reductions in LDL levels. In phase 3 trials, inclisiran showed a reduction in LDL cholesterol levels of up to 52% at month 17, with a good safety ...